Biventricular assist devices and total artificial heart: Strategies and outcomes
- PMID: 36684573
- PMCID: PMC9853410
- DOI: 10.3389/fcvm.2022.972132
Biventricular assist devices and total artificial heart: Strategies and outcomes
Abstract
In contrast to the advanced development of the left ventricular assist device (LVAD) therapy for advanced heart failure, the mechanical circulatory support (MCS) with biventricular assist device (BVAD) and total artificial heart (TAH) options remain challenging. The treatment strategy of BVAD and TAH therapy largely depends on the support duration. For example, an extracorporeal centrifugal pump, typically referred to as a temporary surgical extracorporeal right ventricular assist device, is implanted for the short term with acute right ventricular failure following LVAD implantation. Meanwhile, off-label use of a durable implantable LVAD is a strategy for long-term right ventricular support. Hence, this review focuses on the current treatment strategies and clinical outcomes based on each ventricle support duration. In addition, the issue of heart failure post-heart transplantation (post-HT) is explored. We will discuss MCS therapy options for post-HT recipients.
Keywords: HeartMate 3®; Impella®; ProtekDuo®; Syncardia® TAH; biventricular heart failure; heart transplantation; left ventricular assist device; right heart failure.
Copyright © 2023 Kuroda, Miyagi, Fukamachi and Karimov.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures
References
Publication types
LinkOut - more resources
Full Text Sources
